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Background. Otitismedia (OM) is a common communicable disease that is associatedwith a substantial economic burden.However,
no Korean studies have evaluated OM-related trends after the introduction of the pneumococcal conjugate vaccines. Purpose. This
study aimed to estimate the prevalence and economic burden of OM in Korea using nationally representative data. Methods. The
burden of OM was estimated nationally representative data such as national health insurance claims data from 2012, based on the
prevalence approach and the societal perspective. Results. In 2012, 1,788,303 patients visited medical institutions for treatment of
OM, and the prevalence and burden of OM were 3.5% and 497.35 million US dollars, respectively. Patients who were 0–9 years
old accounted for 59.7% of the cases and 55.2% of the total cost. Among adults, the total and perpatient costs were highest among
50–59-year-old adults. Direct medical costs and outpatient costs accounted for large proportions of the total cost (86.3% and 88.3%,
resp.).Conclusion.The economic burden ofOMdecreased after the introduction of the pneumococcal conjugate vaccines. However,
OM is still associated with a relatively large burden, especially among adults, and interventions are needed to reduce the burden of
OM in this population.
1. Introduction
Otitis media (OM) is a common middle-ear condition and
is particularly common among children [1, 2]. OM typically
presents as acute OM (AOM), which is acute inflammation
of Eustachian tube because of viral and bacterial infections,
or as OM with effusion (OME), which is accumulation of
fluid in the middle ear without acute symptoms, such as
pain and fever [1–4]. Several studies have revealed that >80%
of children experience AOM before they are 5 years old
and that approximately 90% of children experience OME
before they reach school age, especially 6-month-olds to 4-
year-olds [5, 6]. Furthermore, a Korean study revealed that
children who were <9 years old accounted for >90% of
cases that required myringotomy or v-tube to treat AOM [4].
Other studies have found that recurrent AOM during early
childhood is associated with Eustachian tube inefficiency and
that adults with a history of childhood OM exhibit poor
tube function [2, 7]. Moreover, chronic suppurative OM is
the most common cause of hearing disabilities in developing
countries [8], which indicates that childhoodOMmay exhibit
a complicated course and sequelaewith long-term effects.The
annual economic burden of OM in the US is approximately
3–5 billion US dollars (USD), although the real cost may be
higher, because of underestimated indirect costs [9].The total
cost ofAOMinKoreawas reported to be approximately 530.11
million USD in 2004 [4].
Approximately 70% of all AOM cases are caused by
bacteria [3]. The three major bacterial pathogens are Strepto-
coccus pneumoniae, Haemophilus influenzae, and Moraxella
catarrhalis, with S. pneumoniae being the most frequent
pathogen in children with AOM; treatment failure is often
related to antibiotic resistance [10–13]. The incidence of OM
among <10-year-old children was reduced by 22% after the
introduction of the 7-valent pneumococcal conjugate vaccine
(PCV-7), and a further 19% reduction was observed after the
introduction of PCV-13 in the UK [14]. However, in Korea,
only one report has described the economic burden of OM
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using National Health Insurance Service (NHIS) claims data
from 2003, which was before the Korean introduction of
the PCVs [4]. Thus, it is unclear whether the PCVs have
affected the prevalence and burden of OM in Korea. And
the economic burden of OM on each age group is unclear.
Therefore, this study aimed to estimate the prevalence and
economic burden of OM after the PCVs were implemented
in the Korea.
2. Methods
2.1. Ethical Statement. This study was approved by the insti-
tutional review board (1040548-KU-IRB-13-164-A-1).
2.2. Estimation of OM Cases and Cost of Illness Analysis.
The Korean healthcare system is supported by a single
national administrative body (the NHIS). Approximately
97.3% of Koreans were covered by the NHIS in June 2015,
and >99% of Koreans are covered by some form of health
care coverage (including Medical Aid) [15]. Once an NHIS
beneficiary receives healthcare in a medical institution, any
related records are accumulated in a database that is managed
by the NHIS. Therefore, NHIS claims data provide medical
information that is representative of the entire Korean popu-
lation. This study used NHIS claims data from January 1 to
December 31, 2012, to estimate the Korean prevalence and
burden of OM.
Cases of OM were calculated using a prevalence-based
approach and were defined as claims of at least 1 hospital-
ization or at least 2 outpatient visits during the study period.
The diagnostic codes were based on the World Health Orga-
nization’s tenth version of the International Classification of
Disease codes: H65 (nonsuppurative OM), H66 (suppurative
and unspecified OM), H67 (OM in diseases classified else-
where), H68 (Eustachian salpingitis and obstruction), and
H70 (mastoiditis and related conditions) [16]. To calculate the
prevalence of OM, we divided the number of patients with
OM by the registered population of Korean residents from
2012 [17].
We analyzed the economic burden of OM from the
societal perspective, which refers to a comprehensive con-
cept that covers medical costs (e.g., insured and uninsured
medical costs), nonmedical costs (e.g., transportation and
caregiver costs), and lost productivity that is related to work
loss or premature death [18]. Direct medical costs were
estimated using the macrocosting method, and indirect costs
were estimated using the human capital approach. All costs
were converted from Korean won (KRW) to US dollars
(USD) using the mean exchange rate from 2012 (1 USD =
1,126.76KRW) [19].
2.3. Estimation of Direct Costs. We used NHIS claims data to
directly calculate insured costs, such as outpatient and inpa-
tient medical costs. Uncovered medical costs were estimated
by multiplying the uninsured cost rate (uncovered medical
costs divided by total medical costs) from perpatient analyses
that were performed by the NHIS [20]. Pharmaceuticals
costs were estimated using outpatients pharmacy costs, as a
proportion of allmedical costs, from the 2012NationalHealth
Insurance Statistical Annual Report (Table 1) [21].
Direct medical costs were estimated using the following
formula:
Medical cost = ∑
𝑖𝑗
∑(InNHI
𝑖𝑗
+OP
𝑖𝑗
)
+ (OutNHI
𝑖𝑗
+OP
𝑖𝑗
) +OutD
𝑖𝑗
,
(1)
where 𝑖 indicates age (0, 1, 2, . . . , 𝑛 years), 𝑗 indicates sex
(female, male), InNHI indicates the NHI payment for hospi-
talization, OutNHI indicates the NHI payment for outpatient
care, OP indicates the uninsuredmedical costs (out of pocket
payments), and OutD indicates outpatient drug costs.
Nonmedical costs were divided into a transportation cost
and a caregiver cost. For the transportation cost, the numbers
of outpatient visits and hospitalizations were derived from
the NHIS claims data and were multiplied by the pervisit
transportation cost from the Korea Health Panel data [22].
For the caregiver cost, the number of outpatient and hospi-
talization days was derived from the NHIS claims data and
was multiplied by the average daily cost for paid caregivers,
based on the Korea Patient Helper Society suggestions and
the rate of caregiver utilization from the Korea Health Panel
data (Table 1) [22, 23]. However, we assumed that 20–69-
year-old patients had no caregiver costs during outpatient
visits and that the caregiver costs for outpatient visits were 1/3
of the daily caregiver cost (55.861USD). The transportation
costs were defined as 2.169USD per outpatient visit and
20.246USD per hospitalization.
Nonmedical costs were calculated using the following
formula:
Nonmedical cost = ∑
𝑖𝑗
∑{(InV
𝑖𝑗
× InT
𝑖𝑗
)
+ (OutV
𝑖𝑗
×OutT
𝑖𝑗
) + (InD
𝑖𝑗
× CG)
+ (OutV
𝑖𝑗
× CG × 1
3
)} −∑
𝑗
69
∑
𝑖=20
(OutV
𝑖𝑗
× CG
×
1
3
) ,
(2)
where 𝑖 indicates age (0, 1, 2, . . . , 𝑛 years), 𝑗 indicates sex
(female, male), InV indicates the number of inpatient visits,
InT indicates the round-trip transportation cost per inpatient
visit, OutV indicates the number of outpatient visits, OutT
indicates the round-trip transportation cost per outpatient
visit, InD indicates the length of hospitalization, and CG
indicates the daily caregiver cost.
2.4. Estimation of Indirect Costs. Indirect costs were defined
as work-loss costs (interruption of work to visit medical
institutions) and future income loss because of premature
death. The numbers of outpatient visits and hospitalization
days were calculated from the NHIS claims data and were
multiplied by the daily average wage for various types of
employment, based on the Ministry of Employment and
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Table 1: Classification and data sources for costs.
Classification Services included in category Data source
Direct cost
Direct medical costs
Outpatient medical cost NHIS claims data between 2012.1.1 and 2012.12.31.
Inpatient medical cost NHIS claims data between 2012.1.1 and 2012.12.31.
Uninsured medical cost (out
of pocket cost)
Using a ratio for noninsured medical cost per total medical cost surveyed at
NHIS
Pharmaceuticals cost Using a ratio for pharmaceuticals cost per total medical cost published atNHIS and HIRA 2012 National Health Insurance Statistical Yearbook
Direct nonmedical costs
Transportation cost Korea Health Panel Data surveyed at NHIS and KIHASA
Caregiver’s cost
(1) Using a ratio of paid caregiver of Korea Health Panel data surveyed at
NHIS and KIHASA
(2) Using a cost for paid caregiver’s average cost announced at The Korean
Patient Helper Society
Indirect cost
Productivity loss
Due to work loss 2012 Survey Report on Labor Conditions by Employment Type surveyed atMinistry of Employment and Labor
Due to premature death Statistics Korea Data in 2012
∗NHIS: national health insurance service; KIHASA: Korea institute for health and social affairs; HIRA: health insurance review and assessment service.
Labor’s 2012 survey report (Table 1) [24]. However, we
assumed that only 20–69-year-old patients would experience
work loss, and the amount of loss because of outpatient visits
was defined as 1/3 of the daily average wage. The average
daily wages for the analyses were 60.235USD for patients who
were 20–29 years old, 95.301USD for patients who were 30–
39 years old, 120.246USD for patients who were 40–49 years
old, 110.365USD for patients who were 50–59 years old, and
69.841USD for patients who were 60–69 years old.
Work-loss costs were estimated using the following for-
mula:
Work-loss cost
= ∑
𝑖𝑗
∑{(InD
𝑖𝑗
× IC
𝑖𝑗
) + (OutV
𝑖𝑗
×
1
3
× IC
𝑖𝑗
)} ,
(3)
where 𝑖 indicates age (0, 1, 2, . . . , 𝑛 years), 𝑗 indicates sex
(female, male), InD indicates the number of hospitalization
days, IC indicates the daily average wage, and OutV indicates
the number of outpatient visits.
To estimate future income loss, we calculated the rates
of OM-related death from Statistics Korea. The rates were
multiplied by the age- and sex-specific loss amounts that were
calculated using the average annual nominal wage from the
year after death to the average life expectancy and a discount
rate (Table 1) [25]. However, we assumed that individuals who
were ≥70 years old would not earn future income.The cost of
lost future incomewas estimated using the following formula:
Permature death cost = ∑
𝑖
∑
𝑗
𝑛
∑
𝑘
(𝑁
𝑖𝑗
×
𝑌
𝑖𝑗(𝑡+𝑘)
(1 + 𝑟)
𝑘
) , (4)
where 𝑖 indicates age (0, 1, 2, . . . , 𝑛 years), 𝑗 indicates
sex (female, male), 𝑁 indicates the number of deaths
(𝑘: 1, 2, . . . , 𝑛 [𝑛 indicates the difference between life
expectancy and death]), 𝑌
𝑖𝑗(𝑡+𝑘)
indicates the average annual
income at the age of 𝑡 + 𝑘, and 𝑟 indicates the discount rate.
3. Results
In 2012, 1,788,303 Korean patients visitedmedical institutions
for treatment of OM (at least one hospitalization or at
least two outpatient visits). Patients who were 0–9 years old
accounted for 59.7% of all cases. The total prevalence of
OM was 3.5%, although the prevalence was 22.9% among
0–9-year-old patients (Table 2). The mean annual number
of outpatient visits per patient was 6.47, and the highest
number was 7.38 for 0–9-year-old patients.Themean number
of hospitalizations per 100 patients was 2.29, and the highest
number was 4.81 for 50–59-year-old patients. In contrast, 0–
9-year-old patients exhibited a rate of 2 hospitalizations per
100 patients. In addition, the mean duration per hospitaliza-
tion was 5.19 days, which tended to increase with age (0–
9-year old patients: 4.67 days, ≥80-year-old patients: 10.96
days) (Table 3). The numbers of outpatient visits per patient
were 6.75 for male patients and 6.22 for female patients, the
numbers of hospitalizations per 100 patients were 2.33 for
male patients and 2.25 for female patients, and the mean
durations per hospitalization were 5.06 days formale patients
and 5.32 days for female patients; there were no significant
sex-specific differences (Table 4).
Table 5 shows the economic burden of OM among
Koreans based on the direct and indirect costs in 2012. The
total burden was 497.35 million USD, which accounted for
approximately 0.04% of the Korean gross domestic product
in 2012. Direct costs were 429.04 million USD (86.3%), and
indirect costs were 68.31 million USD (13.7%). Among the
direct costs, medical costs were 279.81 million USD (65.2%)
and nonmedical costs were 149.22 million USD (34.8%).
Among the various specific medical costs, outpatient costs
were 135.55 million USD (31.6% of total direct costs), which
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Table 2: Prevalence rate of otitis media by age and gender in 2012.
Age Male Female Total
Number of patients % Prevalence Number of patients % Prevalence Number of patients % Prevalence
0–9 559,308 64.9 23.2 508,340 54.9 22.5 1,067,648 59.7 22.9
10–19 79,274 9.2 2.3 67,147 7.3 2.2 146,421 8.2 2.3
20–29 20,951 2.4 0.6 37,511 4.1 1.2 58,462 3.3 0.9
30–39 37,085 4.3 0.9 66,041 7.1 1.6 103,126 5.8 1.3
40–49 45,872 5.3 1.0 63,432 6.9 1.5 109,304 6.1 1.2
50–59 48,841 5.7 1.2 74,714 8.1 1.9 123,555 6.9 1.6
60–69 37,855 4.4 1.8 53,940 5.8 2.4 91,795 5.1 2.1
70–79 26,568 3.1 2.1 41,977 4.5 2.4 68,545 3.8 2.3
80+ 6,036 0.7 1.9 13,411 1.5 1.7 19,447 1.1 1.8
Total 861,790 100.0 3.4 926,513 100.0 3.6 1,788,303 100.0 3.5
Table 3: Rates of inpatient admissions and outpatient visits due to otitis media by age.
Age
Outpatient Inpatient
Number of
outpatient visits
Number of outpatient
visits (per 1 OM∗
patient)
Number of
inpatient
admissions
Number of inpatient admissions
(per 100 OM∗ patient)
Inpatient hospital days (per
1 OM∗ inpatient admission)
0–9 7,877,576 7.38 21,384 2.00 4.67
10–19 596,280 4.07 1,441 0.98 4.86
20–29 217,858 3.73 944 1.64 5.54
30–39 428,285 4.15 1,924 1.87 5.47
40–49 550,212 5.03 4,086 3.74 5.67
50–59 710,480 5.75 5,937 4.81 5.82
60–69 585,154 6.37 3,694 4.02 5.93
70–79 481,091 7.02 1,276 1.86 6.16
80+ 131,155 6.74 211 1.09 10.96
Total 11,578,091 6.47 40,897 2.29 5.19
∗OM: otitis media.
Table 4: Rates of inpatient admissions and outpatient visits due to otitis media by gender.
Gender
Outpatient Inpatient
Number of
outpatient visits
Number of outpatient visits
(per 1 OM∗ patient)
Number of
inpatient
admissions
Number of inpatient
admissions (per 100 OM∗
patient)
Days of inpatient admission
(per 1 OM∗ inpatient
admission)
Male 5,815,495 6.75 20,093 2.33 5.06
Female 5,762,596 6.22 20,804 2.25 5.32
Total 11,578,091 6.47 40,897 2.29 5.19
∗OM: otitis media.
were followed by uninsured costs (14.7%), pharmaceutical
costs (11.4%), and hospitalization costs (7.5%). Nonmedical
costs included caregiver costs of 123.29 million USD (28.7%
of total direct costs) and transportation costs of 25.93 million
USD (6.0%).
Indirect costs were calculated as the sum of work-loss
costs and lost future income because of OM-related death.
However, we only identified 2 OM-related deaths (both
women who were in their 80s); thus, we defined the cost due
to premature mortality as 0USD. The work-loss costs were
68.31 million USD.
The economic burdens of OM according to age group
and inpatient/outpatient care are presented in Table 6. The
economic burden of inpatient care was 58.12 million USD
(11.7% of the total cost), compared to 439.24 million USD
(88.3%) for outpatient care.The direct costs of hospitalization
were 51.13 million USD (88.0%), and the indirect costs were
7.00 million USD (12.0%). In contrast, the direct costs of
BioMed Research International 5
Table 5: Economic burden of disease due to otitis media for Koreans in 2012.
Classification Cost∗
Direct costs
Direct medical costs
Outpatient medical cost 135.55
Inpatient medical cost 32.06
Uninsured medical cost (out of pocket cost) 63.25
Pharmaceuticals cost 48.95
Direct nonmedical costs Transportation cost for hospital visits 25.93
Caregiver’s cost 123.29
Total, direct costs 429.04
Indirect costs
Productivity loss 68.31
Total, indirect costs 68.31
Total costs 497.35
∗Unit: 1 million US dollar.
1 US dollar = 1,126.76 Korean won (mean exchange rate of 2012).
outpatient care were 377.93 million USD (86.0%), and the
indirect costs were 61.31 million USD (14.0%). Thus, indirect
costs were 2% higher for outpatients, compared to inpatients.
The economic burden of OM-related hospitalization
among 0–9-year-old patients was 16.76 million USD (6.1% of
the total cost in that age group) and the cost of outpatient
care was 257.87 million USD (93.9%). Among 50–59-year-
old patients, the economic burden of hospitalization was
13.49 million USD (24.9% of the total cost in that age
group) and the cost of outpatient care was 40.72 million
USD (75.1%). The highest proportion of inpatient economic
burden was observed among 0–9-year-old patients (28.8%),
which was followed by 23.2% for 50–59-year-old patients and
15.9% for 40–49-year-old patients. The highest proportion of
outpatient economic burden was observed among 0–9-year-
old patients (58.7%), which was followed by 10.9% for 50–
59-year-old patients and 8.4% for 40–49-year-old patients.
The perpatient economic burden was 278.11 USD. The high-
est perpatient burden was observed among 50–59-year-old
patients (438.76USD), which was followed by 393.79USD
for 60–69-year-old patients, 382.52USD for 40–49-year-old
patients, and 312.65USD for 70–79-year-old patients.
4. Discussion
The present study evaluated the prevalence and economic
burden of OM in Korea during 2012. The prevalence of OM
was 3.5%, with 6.47 annual outpatient visits per patient.
Patients who were 0–9 years old had the highest medical
usage, with a prevalence of 22.9% and 7.38 annual outpatient
visits. However, hospitalizations were most common among
50–59-year-old patients (4.81 per year), and 0–9-year-old
patients exhibited a relatively low hospitalization rate (2.00
per year). The total economic burden of OM was estimated
to be 497.35 million USD, which mainly included direct
medical costs (outpatient, caregiver, and uninsured medical
costs, resp.). The indirect costs mainly included work-loss
costs, as mortality-related costs were minimal. Patients who
were 0–9 years old accounted for 28.3% of the total costs
and were followed by the 50–59-year-old and 40–49-year-
old groups. However, the perpatient costs were highest in
the 50–59-year-old group, which was followed by the 60–69-
year-old and 40–49-year-old groups. Studies have focused on
the economic costs and the prevalence of OM in children;
however, few studies have focused on different age groups
as in our study [4, 14, 26, 27]. As far as we know, this is
the first study in Korea to analyze the economic costs and
the hospitalizations for OM in each age group. The reported
prevalence of OM varies according to countries and ethnic
groups [28]. This is complicated by the fact that there is
considerable variation, among studies, in the definition of the
disease. For example, one study stated that the prevalence of
chronic OM ranged from 1% to 46%, which is clearly a wide
range. The Inuit represent the ethnic group with the highest
prevalence of OM, with prevalence ranging from 12 to 46%.
The lowest prevalence of OM was under 1% and reported
in the United States and England. A further study estimated
that the prevalence of AOM and chronic suppurative OM
were 0.22% and 2.89%, respectively, among high-income
residents of the Asia-Pacific region [26]. Our study reported
the prevalence of OM in South Korea as 3.5% and this finding
is consistent with previous studies.
While there is wide variation in the prevalence of
OM among different populations, the prevalence of OM
is declining worldwide with improvements in the use of
antibiotics and vaccinations, healthcare accessibility, and
health behaviors [29]. Nevertheless, OM remains a leading
global cause of healthcare visits and drug prescriptions [26]
and can negatively affect quality of life, as it can cause
permanent hearing impairment. For example, OM accounted
for 1,806,500 disability-adjusted life years (DALYs) globally
during 2013, which corresponds to a 3.1% increase (versus
2005) and is in stark contrast with an 18.5% decrease in the
burden of communicable diseases and a 2.5% decrease in the
burden of all diseases [30]. The OM-related DALYs in Korea
decreased from 19.86 per 100,000 in 1990 to 17.02 per 100,000
in 2013. However, the decreasing trend for OM’s DALY in
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Korea is relatively small, compared to other communicable
diseases (decreased from 2,365 DALYs per 100,000 in 1990
to 1,460 DALYs per 100,000 in 2013). Thus, the burden
of communicable disease decreased by 40% over 23 years,
and the burden of all disease also decreased from 25,435
DALYs per 100,000 in 1990 to 22,925 per 100,000 in 2013
[31], which indicates the increasing relative importance of
OM among communicable and all diseases. For example,
one study found that OM ranked 13th among men and 4th
among women in terms of DALY, with OM-related DALYs
among women increasing from 384 per 100,000 in 2000 to
493 per 100,000 in 2010 [32]. In addition, we found that
3.5% of the Korean population used healthcare because of
OM, and approximately 20% of the 0–9-year-old age group
experienced OM. Furthermore, the economic burden of OM
was estimated to be 497.35 million USD (approximately
0.04%of theKorean gross domestic product in 2012), which is
higher than the burdens for allergic rhinitis [33] or hepatitis
A and hepatitis C [34]. Moreover, the economic burden of
OM accounted for more than half of the burden of breast
cancer [35]. The economic burden of OM is substantial,
despite the fact that there is considerable variability among
studies in terms of the definitions and the inclusion criteria
used as the basis for the calculation of the economic impact.
For example, one study in the US estimated the economic
burden of OM in children at 2.88 billion USD in 2008
[36]. Another study in Australia estimated the economic
burden of OM in a cohort of children from birth to the
age of four years as 138∼339 million USD in 2008 [37].
These results show that OM represents a significant public
health burden, even in developed countries, including Korea.
Furthermore, the need for strategies to minimize this burden
should be highlighted, as communicable diseases generally
affect themost disadvantaged sections of the population, even
in developed countries [38].
Interestingly, we found that the adult prevalence of
OM was highest among the 70–79-year-old age group and
lowest among the 20–29-year-old age group. Another study
estimated the prevalence of chronic OM among adults based
on otoendoscopy findings [29] and revealed that the age-
specific prevalence ranged from 1.1% to 8.5%, with the highest
prevalence observed among adults who were >70 years old.
Therefore, the high prevalence in the 70–79-year-old age
group is likelymainly related to chronicOM.Among children
and adolescents, the highest prevalence was observed in the
0–9-year-old age group (59.7% of all cases), and 0–19-year-
old patients accounted for 67.2% of all cases. Other studies
have also reported relatively high prevalence among children
and adolescents [4, 26], with a 0–16-year-old age group
accounting for 76.4% of all outpatient visits and 75.9% of the
total economic burden in Korea during 2004 [4].
To minimize the burden of OM, PCVs were devel-
oped for S. pneumoniae. In the UK, the incidence of OM
among <10-year-old children was significantly reduced after
the implementation of the PCV-7 and PCV-13 vaccines.
In addition, the introduction of the PCV-13 vaccine in
2010 reduced the American incidence of OM-related visits,
especially among patients who were <2 years old [39]. In
Korea, the PCV-7 and PCV-13 vaccines were introduced in
2003 and 2010, respectively, and the PCV-13 vaccine has
been commonly used as part of the National immunization
program (NIP) since 2014. The economic burden of OM
in 2004 was estimated to be 530.11 million USD, while the
burden in the present studywas estimated to be 497.35million
USD. Therefore, the introduction of the PCV-7 and PCV-
13 vaccines appears to have provided some reduction in the
economic burden. In fact, a comparison of the 1992–1998
cohort (before pneumococcal vaccination) and the 2000–
2003 cohort (after implementing the vaccination) reveals that
the proportion of S. pneumoniae decreased from 48% to
31% and that nontypable H. influenzae has become the most
prevalent organism among children with severe or refractory
AOM.
Many studies regardingOMhave focused on children and
adolescents [29], although the burden of OM among adults
is also becoming important, based on the broader use of
the PCV vaccines (which can prevent OM especially in the
children). For example, adult cases accounted for 36.3% of
outpatient costs and 67.8% of inpatient costs, and the highest
perpatient costs were observed in the 50–59-year-old group,
rather than among children or adolescents. Furthermore, the
highest severity (measured based on admissions per patient)
was observed in the 50–59-year-old group. These results
highlight the fact that the adult burden of OM requires
further attention and interventions to manage this burden.
For example, monitoring the pathogens that are responsible
for OM can improve antimicrobial therapy and prevent
important sequelae, such as hearing loss.
This study has several limitations that warrant consid-
eration. First, we used NHIS claims data to estimate the
economic burden of OM, and this burden may be underes-
timated if a significant proportion of patients do not seek
medical treatment. Moreover, the economic burden could
increase even further if the cost of school absenteeism is taken
into account. Second, the administrative nature of claims
data does not guarantee the accuracy of an OM diagnosis,
although these characteristics have a limited effect in Korea
[40]. Third, the cross-sectional design makes it difficult to
accurately estimate the effect of vaccination on the preva-
lence and burden of OM. Fourth, we did not consider the
otopathogen, whichmakes it difficult to evaluate the effects of
the PCV-7 and PCV-13 vaccines, despite the decrease in the
economic burden. Therefore, additional research is needed
to evaluate the effects of including PCV-13 in the NIP. Fifth,
daycare attendance is a significant risk factor for AOM [25],
and the Korean government recently increased its funding
of daycare centers, with approximately 77.3% of <5-year-old
children attending a daycare center [29]. Therefore, further
research is needed to evaluate how promoting daycare may
affect the prevalence and burden of OM.
In conclusion, the present study used nationally represen-
tative data to estimate the prevalence and economic burden
of OM in Korea during 2012. Our results indicate that the
prevalence of OM was 3.5% and the estimated economic
burden of OM was 497.35 million USD, which is lower than
the reported economic burden from 2004. These decreases
may be related to the use of the PCVs. Nevertheless, the
Korean burden of OM remains substantial, and these trends
8 BioMed Research International
are consistent with worldwide trends. Furthermore, OM
is becoming increasingly important among adults (versus
children and adolescents), with the 50–59-year-old group
exhibiting the highest perpatient cost and the second highest
total cost. Therefore, policy interventions are needed to
reduce the adult burden of OM, and further research is
needed to evaluate the effects of the PCVs on the prevalence
and economic burden of OM.
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